Commenting on the DEA's Tryptamine Scheduling Proposal

Wed, 30 Sep 2026 00:00:00 +0000

On September 23, the DEA proposed placing five tryptamines in Schedule I: 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT. Scheduling is a formal rulemaking “on the record,” and a final rule is reviewed for substantial evidence. So I read the notice for what it concedes:

The evidence is pooled across five substances. For 4-OH-DiPT it is one multi-substance poison-center case. For DiPT it is two.
The DEA says diversion “is not applicable” and that dependence liability cannot be determined.
Human effects rest on “anecdotal reports usually on internet forums.”
The finding that people use these substances without medical advice is assumed because the substances are unapproved, which is circular.
The small-business analysis divides by entire industries, and its own footnote says 0.02% where the text says 0.18%.

The comments are due October 23 at regulations.gov under docket DEA1715. You don’t need standing or evidence to file.

Policy on Brambles

Commenting on the DEA's Tryptamine Scheduling Proposal